Search Results
Aug 19, 2026, 19:52 ET Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm
Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Immunovant, Inc. (NASDAQ: IMVT) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and
More news about: Kuehn Law, PLLC
Feb 17, 2026, 10:48 ET SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)
multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-purcell--lefkowitz-llp-announces-shareholder-investigation-of-immunovant-inc-nasdaq-imvt-302689521.htmlSOURCE
More news about: Purcell & Lefkowitz LLP
Jan 05, 2026, 12:00 ET SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)
Jan. 5, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Immunovant, Inc. (NASDAQ: IMVT) on behalf of the company's shareholders. The investigation seeks to determine whether Immunovant, Inc.'s directors breached their fiduciary duties
More news about: Purcell & Lefkowitz LLP
Oct 02, 2025, 17:31 ET Graves' Orbitopathy Market to Exhibit Growth at a CAGR of 19.8% During the Forecast Period (2025-2034) | DelveInsight
orbitopathy therapies in clinical trials include Veligrotug (VRDN-001), VRDN-003, Efgartigimod PH20 SC, ENSPRYNG (satralizumab; RG6168), Batoclimab (IMVT-1401; RVT-1401), Linsitinib, Pacibekitug (TOUR006), LASN01, Lonigutamab, and others. Discover the new
More news about: DelveInsight Business Research, LLP